Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133305 | 1.00 | ITGB3 (0.48) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL214303 | 1.00 | ITGB3 (0.48) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| Tert-Butyl Formate SCHEMBL27649833 | 0.92 | ITGB3 (0.45) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| Imidazole SCHEMBL7290626 | 0.91 | ITGB3 (0.42) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL30364981 | 0.91 | KMT2A (0.44) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL8525625 | 0.90 | ITGB3 (0.41) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL29520630 | 0.90 | ITGB3 (0.39) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL10537834 | 0.90 | ACE (0.44) | ITGB3ITGA2BACEPTPN1PPARA | |
| SCHEMBL30400222 | 0.90 | ITGB3 (0.39) | ITGB3ITGA2BACEPTPN1ITGA4 | |
| SCHEMBL30629214 | 0.90 | CTSS (0.42) | ITGB3ITGA2BACEPTPN1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 575 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504926-A | Method for preparing Boc-His (Trt) -Aib-OH | 常州吉恩药业有限公司 | 2025-02-25 | — | — | CN | claimed |
| CN-119306667-A | Preparation method of amino acid derivative containing side chain amino protection | 四川鸿日医药科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-118955683-A | Semex lattice Synthesis method of lupeptide | 泰州兴普泰生物制药有限公司 | 2024-11-15 | — | — | CN | claimed |
| CN-114401981-B | Glucagon production method | 北京费森尤斯卡比医药有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-117007704-B | Liquid phase analysis method for quantitatively detecting isomer content in dipeptide | 南京汉欣医药科技有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-117986349-B | Semex lattice preparation method of lupeptide | 福建基诺厚普生物科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118005766-B | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-111944039-B | Synthetic method of somalupeptide | 深圳市健元医药科技有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-118562020-A | Glu-His-Gly trimer, preparation and application thereof in enhancing immunity | 首都医科大学 | 2024-08-30 | — | — | CN | claimed |
| CN-118005766-A | Solid phase synthesis method of Glepaglutide | 杭州信海医药科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-114790236-A | Synthetic method of GCGR/GLP-1R double-target-point agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-111153983-B | Semisynthesis preparation method of somaglutide | 江南大学 | 2022-07-01 | — | — | CN | claimed |
| CN-114401981-A | Process for producing glucagon | 北京费森尤斯卡比医药有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-112010926-B | KGH and hydroxymethyl modified benzimidazole quinazolines, synthesis, activity and applications thereof | 首都医科大学 | 2022-04-22 | — | — | CN | claimed |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | Indian Institute of Technology Indore (IN) | 2022-02-24 | — | — | US | claimed |
| CN-114075273-A | Preparation method of GLP-1 analogue fragment activated ester | 四川科伦药物研究院有限公司 | 2022-02-22 | — | — | CN | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| US-6951946-B2 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | LEXICON PHARMACEUTICALS, INC. (US) | 2005-10-04 | — | — | US | claimed |
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | KOLB HARTMUTH C (US) | 2005-07-14 | — | — | US | claimed |
| US-20040019215-A1 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | LEXICON PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | ITGB3 4792/4885ITGA2B 4745/4885ACE 2382/4885 |
| US-20050154211-A1 | Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates | OXA1L, ODC1, CYP4B1 | ITGB3 539/4885ITGA2B 1904/4885ACE 1014/4885 |
| US-20220056079-A1 | THIRD GENERATION TUBULYSIN ANALOGUES AND PROCESS OF PREPARATION THEREOF | TEK, VIP, SCTR | ITGB3 1053/4885ITGA2B 1930/4885ACE 1129/4885 |
| US-20040019215-A1 | Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates | OXA1L, ODC1, CYP4B1 | ITGB3 539/4885ITGA2B 1904/4885ACE 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.